+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07687017

Selective Removal of C-Reactive Protein Using PentraSorb4-CRP in Patients with Cardiogenic Shock Following Acute Myocardial Infarction

Led by Leipzig Heart Science gGmbH · Updated on 2026-10-27

50

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Cardiogenic shock following an acute myocardial infarction is linked to high short-term death rates despite current treatments. This condition causes a strong inflammatory response, with elevated C-reactive protein CRP believed to worsen heart damage and organ problems. Researchers are studying whether removing CRP from the blood can improve outcomes in these patients. This trial compares standard care alone to standard care plus selective CRP removal through a procedure called CRP apheresis using the PentraSorb4-CRP device. Participants receiving CRP apheresis undergo up to three sessions starting within about 5 hours after randomization, with additional sessions at approximately 30 and 54 hours. The study is a randomized, open-label pilot across multiple centers. Participants are closely monitored with repeated assessments of the CLIP score, a measure of risk, at around 66 hours after randomization and earlier timepoints. Other outcomes include death rates, heart and kidney function markers, inflammatory biomarkers, and safety events like bleeding or infection. The study runs until about 30 days post-treatment, with data collection continuing until October 2027.

CONDITIONS

Brief Title

CRP Apheresis in Infarct-Related Cardiogenic Shock

Research Team

C

CRP-SHOCK Leipzig Heart Science gGmbH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here